# US 10,765,659 B2 · Potentiated tulathromycin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,659 B2
- Document ID: US10765659B2
- Status: Granted
- Kind: B2
- Application number: 16/084,804
- Filed: 2017-03-14
- Published: 2019-03-28
- Granted: 2020-09-08
- Earliest claimed: 2016-03-14
- Assignees: Septeos
- Applicants: Septeos
- Inventors: Nicolas Tesse
- Web page: https://patentgrep.com/patent/US10765659B2

## CPC

- A61K 31/365: Lactones
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to enhanced tulathromycin for use in the treatment, metaphylaxis or prevention of a microbial infection, characterized in that a compound of formula (I) is used in combination with tulathromycin at a weight ratio compound of formula (I):microbial agent of 8:1 to 1:10, and in that the microbial infection is induced in particular by a strain A pathogen in which the concentration of compound (I) satisfies the following equation: [C]<[MIC]/x, where [C] is the concentration according to the invention of compound (I) to be used in strain A, [MIC] is the minimum inhibitory concentration measured for compound (I) alone in strain A, and x is at least 100, advantageously at least 1000, more advantageously between 2000 and 10,000, or even greater than 50,000.

## Claims

### Claim 1

A method for treating a microbial infection in an animal, in need thereof, comprising co-administering tulathromycin and cineole; with a cineole:tulathromycin mass ratio varying from 8:1 to 1:10, and wherein the microbial infection is induced by a microbial pathogen and the concentration of cineole ([C]) is <[MIC]/x where [MIC] is the minimal inhibitory concentration measured for cineole alone, for the microbial pathogen and x is from 100 to 10,000.

### Claim 2 (depends on 1)

The method according to claim 1, wherein x is greater than 1000.

### Claim 3 (depends on 1)

The method according to claim 1, wherein x is between 2000 and 10,000.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the cineole: tulathromycin mass ratio varies from 4:1 to 1:10.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the cineole: tulathromycin mass ratio varies from 1:1 to 1:10.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the cineole: tulathromycin mass ratio varies from 1:1 to 1:5.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the dose of cineole is between 0.01 and 64 mg/kg.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the dose of cineole is between 0.1 and 30 mg/kg.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the dose of cineole is between 0.5 and 10 mg/kg.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the dose of tulathromycin is between 0.01 and 64 mg/kg.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the dose of tulathromycin is between 0.1 and 30 mg/kg.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the dose of tulathromycin is between 0.5 and 10 mg/kg.

### Claim 13 (depends on 1)

The method according to claim 1, wherein tulathromycin is administered at a dose of 2.5 mg/kg, and the dose of cineole varies between 0.75 mg/kg and 2.5 mg/kg.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the dose of cineole varies between 0.75 mg/kg and 2 mg/kg.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the cineole is adapted for systemic administration.

### Claim 16

A method for metaphylaxis of a microbial infection in an animal, in need thereof, comprising coadministering tulathromycin and cineole; with a cineole: tulathromycin mass ratio varying from 8:1 to 1:10, and wherein the microbial infection is induced by a microbial pathogen and the concentration of cineole ([C]) is <[MIC]/x where [MIC] is the minimal inhibitory concentration measured for cineole alone, for the microbial pathogen and x is from 100 to 10,000.